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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To systematically review the clinical effects, efficacy and safety of pharmacological augmentation for clozapine in treatment-resistant
schizoaffective disorder.
B A C K G R O U N D
Description of the condition
Schizoaffective disorder is a chronic and severe mental illness,
with a prevalence of 0.5% to 0.8% in the general population
(Malhi 2008). For many people it follows a relapsing and remit-
ting course, with periods of remission, interspersed with florid
psychotic episodes and concurrent mood symptoms, eithermania,
mixed or depressive episodes. The classification of schizoaffective
disorder as a separate condition to schizophrenia and bipolar af-
fective disorder remains controversial, but it retains its place in
diagnostic classification manuals as a standalone condition (APA
2013), with outcomes somewhere between those of schizophre-
nia and bipolar affective disorder (Harrow 2000; Marneros 2001;
Mancuso 2014; Tondo 2016).
Treatment-resistant schizoaffective disorder occurs in a minority
of patients in which their response to antipsychotic medication
or mood stabilisers, or both, is suboptimal. For these people, this
means that persistent psychotic symptoms with accompanying af-
fective change (hypomanic/manic or mixed or depressive) is the
predominant clinical presentation, with poor functioning despite
adequate treatment with antipsychotic medication or mood sta-
bilisers, or both. There is no consensual definition of treatment
resistance in schizoaffective disorder, making it difficult to esti-
mate the number of treatment-resistant schizoaffective patients,
but clinical experience indicates that some people with schizoaf-
fective disorder demonstrate suboptimal clinical response at some
point in the longitudinal course of their illness (Mancuso 2014;
Tondo 2016).
Treatment options are restricted, with clozapine the only drugwith
established efficacy in treatment-resistant schizophrenia (Kane
1988; Meltzer 1989; Wahlbeck 1999; Chakos 2001; McEvoy
2006), with emerging evidence for its effectiveness in treatment-
resistant bipolar affective disorder (Li 2015), and it is similarly used
in treatment-resistant schizoaffective disorder (McElroy 1991;
Banov 1994; Ciapparelli 2003).
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Description of the intervention
Clozapine has shown efficacy in treating acute mania, decreas-
ing depressive symptoms and in overall mood stabilisation (Gitlin
2006; Li 2015). Clozapine is the medication of choice in treat-
ment-resistant psychotic disorders including schizoaffective dis-
order, producing a clinically effective response in 50% to 60%
of those with treatment-resistant schizophrenia (Meltzer 1989;
Meltzer 1992). A large, uncontrolled body of literature suggests
that clozapine can be considered as a treatment for refractory
schizoaffective disorder and bipolar affective disorder, similarly to
its use in treating schizophrenia (Frye 1998; Li 2015).
For the 30% of treatment-resistant schizophrenia patients who
fail to respond to clozapine, there are no evidence-based effective
treatments (Meltzer 1992; Cipriani 2009; Sommer 2012), with
clozapine typically being augmented with different mood stabilis-
ers and antipsychotic medication (Porcelli 2012; Sommer 2012).
A similar strategy is used in the management of schizoaffective
disorder (McElroy 1991; Ciapparelli 2003).
We will define augmentation as the coadministration of different
classes of medications or alternative antipsychotic medications to
augment clozapine effectiveness. For example this might refer to
the coadministration of first generation antipsychotics (FGAs) or
second generation antipsychotics (SGAs), or mood stabilisers, an-
tidepressants, or benzodiazepines, rather than add on therapies to
treat adverse effects of clozapine treatment.
Mood stabilisers are medications which are effective in the acute
treatment of manic symptoms or depressive symptoms, or both,
and the prevention of manic or depressive symptoms. We have
included here, as mood stabilisers, medications that preferentially
act on and prevent relapse to the affective poles of the schizoaffec-
tive illness spectrum (e.g. mania or depression, without ill effect
on the other) (Ketter 2002; Bauer 2004).
How the intervention might work
The exact mechanism of action of antipsychotics and mood sta-
bilisers in schizoaffective disorder and other psychotic disorders
is unknown. Mood stabilisers act on a diverse range of molecu-
lar and cellular targets and are thought to cause a range of direct
effects on neural transmission, as well as downstream effects on
neural and synaptic plasticity. Clozapine and other antipsychotic
medications are thought to have mood-stabilising effects through
their central dopamine and 5-HT2A actions. The mechanism of
clozapine as an antipsychotic of superior efficacy, and as a mood
stabilising agent remain unclear. Clozapine has affinity at multi-
ple neurotransmitter receptors in the brain, which may potentially
mediate its efficacy, including dopamine (D1, D2, D4), serotonin
(5HT2A, 5HT2C, 5HT6,5HT7),muscarinic (M1,M2,M3,M4,
M5) and adrenergic (alpha-1 and alpha-2) receptors (Miyamoto
2012). Other antipsychotic medications interact with some or
all of these same receptors contributing to potential mechanisms
of efficacy as antimanic, antidepressant and mood stabilisation
agents. D2 receptor antagonism is thought to mediate anti-manic
effects of antipsychotics (Cipriani 2011). Partial agonist activity
at 5-HT1A receptors (which most SGAs have) may contribute
to their efficacy against depression, as well as negative symptoms
of schizophrenia (Miyamoto 2012). Antagonsim at 5-HT2C re-
ceptors is reported to aid antidepressant action in SGAs (Jensen
2010). Antagonism at 5-HT6 and 5-HT7 receptors has been pos-
tulated to aid antidepressant effects (Nikiforuk 2015).
Lithium carbonate and anticonvulsant medications, such as
sodium valproate and lamotrigine, function as mood-stabilising
agents. Lithium carbonate broadly acts to stabilise neuronal activ-
ities, support neural plasticity, and provide neuroprotection (Jope
1999; Malhi 2013). It functions to modify neurotransmission, re-
ducing excitatory (dopamine and glutamate), but increasing in-
hibitory (gamma-aminobutyric acid (GABA)) neurotransmission;
modulating signalling linked to neural plasticity, including acting
on cyclic AMP-dependent kinase, and protein kinase C; modu-
lating second-messenger systems and gene expression; and having
a neuroprotective effect by increasing proteins such as brain-de-
rived neurotrophic factor and reducing oxidative stress (Jope 1999;
Malhi 2013). Anticonvulsant mood stabilisers share similarities
as well as differences with lithium, in their mechanism of action.
They act to modulate regulatory and inhibitory neurotransmis-
sion, signal transduction and gene expression, and with possible
neuroprotective effects (Cipriani 2011; Cipriani 2013). However,
it remains unknown how these medications work in combination
with clozapine in treatment-resistant schizoaffective disorder.
Why it is important to do this review
It is not possible at present to make reliable suggestions for the
choice of the best augmentation strategy in people with schizoaf-
fective disorder resistant to clozapine. This is due to the lack of clear
guidelines about this difficult therapeutic challenge. A Cochrane
review has already been published to assess the efficacy and safety
of clozapine augmentation with other antipsychotic medication
in people with treatment-resistant schizophrenia (Cipriani 2009).
In schizoaffective disorder treatment, available data are almost ex-
clusively provided as sub-group analyses from schizophrenia trials
(Marneros 2001). In relation to the pharmacotherapeuticmanage-
ment of clozapine-refractory schizoaffective disorder, the literature
is dominated by case studies and open label trials. Hence from a
clinical perspective, very real questions arise about the best evi-
dence-based treatments in this disorder, questions which become
more challenging to answer in those with a clozapine-refractory
illness (as for example, there may need to be a greater considera-
tion for augmenting clozapine with mood stabilizers). As a result
there is a need for this review to determine the most efficacious
and well-tolerated treatments in clozapine-resistant schizoaffective
disorder.
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O B J E C T I V E S
To systematically review the clinical effects, efficacy and safety of
pharmacological augmentation for clozapine in treatment-resis-
tant schizoaffective disorder.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All relevant randomised controlled trials. If a trial is described as
’double blind’ but implies randomisation, we will include such tri-
als in a sensitivity analysis (Sensitivity analysis). If their inclusion
does not result in a substantive difference, they will remain in the
analyses. If their inclusion does result in important clinically sig-
nificant but not necessarily statistically significant differences, we
will not add the data from these lower quality studies to the results
of the better trials, but will present such data within a subcategory.
We will exclude quasi-randomised studies, such as those allocating
by alternate days of the week. Where people are given additional
treatments within the treatment groups, we will only include data
if the adjunct treatment is evenly distributed between groups and
it is only the augmentation agent that is randomised.
Types of participants
Adults (18 years or more), however defined, with schizoaffective
disorder by any means of diagnosis who remain resistant to cloza-
pine treatment. We will include trials with a mix of diagnosis, in-
cluding those where schizoaffective disorder is not in the majority.
We will include such mixed-diagnosis trials only if trial data relat-
ing to those individuals with schizoaffective disorder are available.
We are interested in making sure that information is as relevant to
the current care of people with schizoaffective disorder as possible
so propose, where possible, to clearly highlight the current clini-
cal state (acute, early post-acute, partial remission, remission) as
well as the stage (prodromal, first episode, early illness, persistent)
and as to whether the studies primarily focused on people with
particular problems (for example, negative symptoms, treatment-
resistant illnesses).
Types of interventions
1. Any pharmacological intervention at any dose or route of ad-
ministration whose primary aim is to augment clozapine in treat-
ment-resistant schizoaffective disorder, e.g.
• Clozapine plus another antipsychotic medication
• Clozapine plus a mood stabiliser
• Clozapine plus an antidepressant medication
• Clozapine plus other treatments
We will investigate the following in trials: comparing clozapine
plus augmentation drug versus clozapine alone, or clozapine plus
augmentation drug versus augmentation drug alone, or placebo
or any comparator.
Types of outcome measures
If possible, we will divide outcomes into short term (less than 3
months), medium term (up to 6 months) and long term (longer
than 6 months). For any outcome assessed more than once in a
particular term, we will extract data for each timepoint.
Primary outcomes
1. Mental state
1.1 Clinically important response in psychotic or affective symp-
toms, as defined by each of the studies (short term)
2. Service utilisation
2.1 Hospital admission, re-admission, or both
2.2 Days in hospital
Secondary outcomes
1. Leaving the study early
2. Global state
2.1 Average endpoint score or change score in global state
2.2 Clinically important response on global state, as defined by
each of the studies
3. Mental State
3.1Average endpoint score or change score in psychotic or affective
symptoms
3.2 Clinically important response in specific symptoms, as defined
by each of the studies
3Clozapine augmentation for treatment-resistant schizoaffective disorder (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
3.2.1 Positive symptoms
3.2.2 Negative symptoms
3.2.3 Manic symptoms
3.2.4 Depressive symptoms
3.3 Average endpoint score or change score in specific symptoms,
as defined by each of the studies
3.3.1 Positive symptoms
3.3.2 Negative symptoms
3.3.3 Manic symptoms
3.3.4 Depressive symptoms
3.4 Recurrence of any affective or psychotic episodes - as measured
by institution of additional treatment for affective or psychotic
episode and time to institution
4. Adverse events: numbers of participants experiencing
4.1 Blood dyscrasias such as neutropenia or agranulocytosis
4.2 Metabolic adverse effects (including weight gain, dyslipi-
daemia and glucose dysregulation)
4.3 Extrapyramidal adverse effects
4.4 Gastrointestinal side effects: constipation, nausea, vomiting,
dyspepsia
4.5 Central nervous system side effects: tremor, sedation, ataxia,
cognitive impairment.
4.6Cardiovascular adverse effects: tachycardia,QTc prolongation,
hypertension or hypotension, myocarditis or cardiomyopathy
5. Other adverse effects
5.1 General and specific effects (including deaths by suicide or
natural causes)
5.2 Average endpoint or change scores in adverse effects
5.2 Mortality due to agranulocytosis or haematological adverse
effects
5.3 Mortality due to myocarditis or cardiovascular adverse effects
5.4 Rates of deliberate self-harm
6. Service utilisation outcomes
6.1 Days in hospital
7. Economic outcomes
7.1 Direct costs of care
7.2 Indirect costs of care
8. Quality of life
8.1 Significant important change in quality of life, as defined by
each of the studies
8.2 Average endpoint of change score in quality of life
9. Satisfaction with care/treatment for either recipients of
care or carers
9.1 Significant important change in satisfaction with care/treat-
ment, as defined by each of the studies
9.2 Average endpoint of change score in satisfaction with care/
treatment
’Summary of findings’ table/s
We will use the GRADE approach to interpret findings (
Schünemann 2008); andwill useGRADEprofiler (GRADEPRO)
to import data fromRevMan 5 (Review Manager) to create ’Sum-
mary of findings’ table/s. These tables provide outcome-specific
information concerning the overall quality of evidence from each
included study in the comparison, the magnitude of effect of the
interventions examined, and the sum of available data on all out-
comes we rated as important to patient care and decision making.
We aim to select the following main outcomes for inclusion in the
’Summary of findings’ table/s:
• Mental state: Clinically important response - psychotic
symptoms
• Mental state: Clinically important response - affective
symptoms
• Service utilisation: Hospital admission, re-admission or
both
• Leaving the study early
• Adverse events: Any significant adverse effects
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• Economic outcomes
• Quality of life
Search methods for identification of studies
Electronic searches
Cochrane Schizophrenia Group’s Trials Register
The Trials Search Co-ordinator (TSC) will search the Cochrane
Schizophrenia Group’s Study-Based Register of Trials using the
following search strategy:
*Clozapine* in Intervention of STUDY
In such study-based registers, searching themajor concept retrieves
all the relevant keywords and studies because all the studies have
already been organised based on their interventions and linked to
the relevant topics.
The Cochrane Schizophrenia Group’s Register of Trials is com-
piled by systematic searches of major resources (including AMED,
BIOSIS, CINAHL, EMBASE,MEDLINE, PsycINFO, PubMed,
and registries of clinical trials) and their monthly updates, hand-
searches, grey literature, and conference proceedings (see Group
Module). There are no language, date, document type, or publi-
cation status limitations for inclusion of records into the register.
Searching other resources
1. Reference searching
We will inspect references of all included studies for further rele-
vant studies.
2. Personal contact
We will contact the first author of each included study for infor-
mation regarding unpublished trials. We will note the outcome of
this contact in the tables of ’Characteristics of included studies’ or
’Characteristics of studies awaiting classification’.
Data collection and analysis
Selection of studies
JL and JT will independently inspect citations from the searches
and identify relevant abstracts. JM will re-inspect a random 20%
sample to ensure reliability. Where disputes arise, we will acquire
the full report for more detailed scrutiny. JL and JT will obtain
and inspect full reports of the abstracts meeting the review criteria.
Again, JM will re-inspect a random 20% of reports in order to
ensure reliable selection. Where it is not possible to resolve dis-
agreement by discussion, we will attempt to contact the authors
of the study for clarification.
Data extraction and management
1. Extraction
Review authors JL and JT will extract data from all included stud-
ies. In addition, to ensure reliability, JMwill independently extract
data from a random sample of these studies, comprising 10% of
the total. Again, we will discuss and document any disagreement
and, if necessary, we will contact authors of studies for clarifica-
tion. We will attempt to extract data presented only in graphs and
figures whenever possible, but will include only if two reviewers
independently have the same result. We will attempt to contact
authors through an open-ended request in order to obtain missing
information or for clarification whenever necessary. If studies are
multi-centre, where possible we will extract data relevant to each
component centre separately.
2. Management
2.1 Forms
We will extract data onto standard, simple forms.
2.2 Scale-derived data
We will include continuous data from rating scales only if:
a) the psychometric properties of the measuring instrument have
been described in a peer-reviewed journal (Marshall 2000); and
b) the measuring instrument has not been written or modified by
one of the trialists for that particular trial.
Ideally the measuring instrument should either be i. a self-report
or ii. completed by an independent rater (not the therapist). We
realise that this is not often reported clearly; in ’Description of
studies’ we will note if this is the case or not.
2.3 Endpoint versus change data
There are advantages of both endpoint and change data. Change
data can remove a component of between-person variability from
the analysis. On the other hand calculation of change needs two
assessments (baseline and endpoint) which can be difficult in un-
stable and difficult-to-measure conditions such as schizophrenia.
We have decided to primarily use endpoint data, and only use
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change data if the former are not available. If appropriate we will
combine endpoint and change data in the analysis as we aim to use
mean differences (MD) rather than standardised mean differences
throughout (Higgins 2011).
2.4 Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we aim to apply the following stan-
dards:
For large studies and change data:
We will use data from studies of at least 200 participants, for
example, in the analysis irrespective of the following rules, because
skewed data pose less of a problem in large studies. We will also
enter change data as when continuous data are presented on a scale
that includes a possibility of negative values (such as change data),
it is difficult to tell whether data are skewed or not.We will present
and enter change data into statistical analyses.
For endpoint data from smaller studies (under 200 participants):
(a) when a scale starts from the nite number zero, we will subtract
the lowest possible value from the mean, and divide this by the
standard deviation. If this value is lower than 1, it strongly suggests
a skew and we will exclude these data. If this ratio is higher than
1 but below 2, there is suggestion of skew. We will enter such
data and test whether its inclusion or exclusion would change
the results substantially. Finally, if the ratio is larger than 2 we
will include these data, because skew is less likely (Altman 1996;
Higgins 2011).
b) if a scale starts from a positive value (such as the Positive and
Negative Syndrome Scale (PANSS), (Kay 1986) which can have
values from 30 to 210), we will modify the calculation described
above to take the scale starting point into account. In these cases
skew is present if 2 SD > (S − S min), where S is the mean score
and ’S min’ is the minimum score.
2.5 Common measure
To facilitate comparison between trials, we intend, where possible,
to convert variables that can be reported in different metrics, such
as days in hospital (mean days per year, per week or per month)
to a common metric (e.g. mean days per month).
2.6 Conversion of continuous to binary
Where possible, we will make efforts to convert outcome measures
to dichotomous data. This can be done by identifying cut-off
points on rating scales and dividing participants accordingly into
’clinically improved’ or ’not clinically improved’. It is generally
assumed that if there is a 20% reduction in a scale-derived score
such as the Brief Psychiatric Rating Scale (BPRS, Overall 1962)
or the Positive and Negative Syndrome Scale (PANSS, Kay 1986),
this could be considered as a clinically significant response (Leucht
2005). If data based on these thresholds are not available, we will
use the primary cut-off presented by the original authors.
2.7 Direction of graphs
Where possible, we will enter data in such a way that the area
to the left of the line of no effect indicates a favourable outcome
for pharmacological augmentation of clozapine.Where keeping to
this makes it impossible to avoid outcome titles with clumsy dou-
ble-negatives (e.g. ’Not un-improved’) we will report data where
the left of the line indicates an unfavourable outcome and make a
note in the relevant graphs.
Assessment of risk of bias in included studies
Again review authors JL and JT will work independently to assess
risk of bias by using criteria described in the Cochrane Handbook
for Systematic Reviews of Interventions to assess trial quality (Higgins
2011). This set of criteria is based on evidence of associations
between overestimate of effect and high risk of bias of the article
such as sequence generation, allocation concealment, blinding,
incomplete outcome data and selective reporting.
If the raters disagree, we will make the final rating by consensus,
with the involvement of JM. Where inadequate details of ran-
domisation and other characteristics of trials are provided, we will
contact authors of the studies in order to obtain further informa-
tion. We will report non-concurrence in quality assessment, but if
disputes arise as to which category a trial is to be allocated, again
we will resolve by discussion.
We will note the level of risk of bias in the text of the review,
Summary figures, and in the ’Summary of findings’ table/s.
Measures of treatment effect
1. Binary data
For binary outcomes we will calculate a standard estimation of the
risk ratio (RR) and its 95% confidence interval (CI). It has been
shown that RR is more intuitive than odds ratios (Boissel 1999);
and that odds ratios tend to be interpreted as RR by clinicians
(Deeks 2000). The number needed to treat for an additional ben-
eficial outcome (NNTB) and number needed to treat for an addi-
tional harmful outcome (NNTH) with their confidence intervals
are intuitively attractive to clinicians but are problematic both in
accurate calculation in meta-analyses and interpretation (Hutton
2009). For binary data presented in the ’Summary of findings’
table/s we will, where possible, calculate illustrative comparative
risks.
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2. Continuous data
For continuous outcomes we will estimate mean difference (MD)
between groups. We prefer not to calculate effect size measures
(standardised mean difference (SMD)). However, if scales of very
considerable similarity are used, we will presume there is a small
difference in measurement, and we will calculate effect size and
transform the effect back to the units of one or more of the specific
instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data poses problems. Firstly, authors often fail to account
for intra-class correlation in clustered studies, leading to a ’unit
of analysis’ error (Divine 1992), whereby P values are spuriously
low, confidence intervals unduly narrow and statistical significance
overestimated. This causes type I errors (Bland 1997; Gulliford
1999).
• Where clustering is not accounted for in primary studies,
we will present data in a table, with a (*) symbol to indicate the
presence of a probable unit of analysis error. We will contact first
authors of studies to attempt to obtain intra-class correlation
coefficients for their clustered data and to adjust for this by using
accepted methods (Gulliford 1999).
• Where clustering has been incorporated into the analysis of
primary studies, we will present these data as if from a non-
cluster randomised study, but adjust for the clustering effect. We
have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a ’design
effect’. This is calculated using the mean number of participants
per cluster (m) and the intra-class correlation coefficient (ICC)
[Design effect = 1 + (m − 1)*ICC] (Donner 2002). If the ICC is
not reported we will assume it to be 0.1 (Ukoumunne 1999). If
cluster studies have been appropriately analysed taking into
account intra-class correlation coefficients and relevant data
documented in the report, synthesis with other studies will be
possible using the generic inverse variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect. This
occurs if an effect (e.g. pharmacological, physiological or psycho-
logical) of the treatment in the first phase is carried over to the
second phase. As a consequence on entry to the second phase the
participants can differ systematically from their initial state despite
a wash-out phase. For the same reason cross-over trials are not ap-
propriate if the condition of interest is unstable (Elbourne 2002).
As both effects are very likely in severe mental illness, we will only
use data from the first phase of cross-over studies.
3. Studies with multiple treatment groups
Where a study involves more than two treatment arms, if relevant,
we will present the additional treatment arms in comparisons. If
data are binary wewill simply add and combine within the two-by-
two table. If data are continuous we will combine data following
the formula in section7.7.3.8 (Combining groups) of theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Where the additional treatment arms are not relevant, we will not
use these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow-up, data must lose credibility (Xia
2009). We choose that, for any particular outcome, should more
than 50% of data be unaccounted for, we will not reproduce these
data or use them within analyses. If, however, more than 50% of
those in one arm of a study are lost, but the total loss is less than
50%, we will address this within the ’Summary of findings’ table/
s by down-rating quality. Finally, we will also downgrade quality
within the ’Summary of findings’ table/s should loss be 25% to
50% in total.
2. Binary
In the case where attrition for a binary outcome is between 0% and
50% andwhere these data are not clearly described, wewill present
data on a ’once-randomised-always-analyse’ basis (an intention-
to-treat analysis). Those leaving the study early are all assumed to
have the same rates of negative outcome as those who completed,
with the exception of the outcome of death and adverse effects.
For these outcomes the rate of those who stay in the study - in
that particular arm of the trial - will be used for those who did
not. We will undertake a sensitivity analysis testing how prone the
primary outcomes are to change when data only from people who
complete the study to that point are compared to the intention-
to-treat analysis using the above assumptions.
3. Continuous
3.1 Attrition
We will use data where attrition for a continuous outcome is be-
tween 0% and 50%, and data only from people who complete the
study to that point are reported.
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3.2 Standard deviations
If standard deviations are not reported, we will first try to obtain
the missing values from the authors. If not available, where there
are missing measures of variance for continuous data, but an exact
standard error and confidence intervals available for group means,
and either P value or ’t’ value available for differences in mean,
we can calculate them according to the rules described in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011): When only the standard error (SE) is reported, standard
deviations (SDs) are calculated by the formula SD = SE *
√
(n).
Chapters 7.7.3 and 16.1.3 of theCochraneHandbook for Systematic
Reviews of Interventions present detailed formulae for estimating
SDs from P values, t or F values, confidence intervals, ranges or
other statistics (Higgins 2011). If these formula do not apply,
we will calculate the SDs according to a validated imputation
method which is based on the SDs of the other included studies
(Furukawa 2006). Although some of these imputation strategies
can introduce error, the alternative would be to exclude a given
study’s outcome and thus to lose information. We neverthelesswill
examine the validity of the imputations in a sensitivity analysis
excluding imputed values.
3.3 Assumptions about participants who left the trials early
or were lost to follow-up
Various methods are available to account for participants who left
the trials early or were lost to follow-up. Some trials just present the
results of study completers, others use the method of last observa-
tion carried forward (LOCF), while more recently methods such
as multiple imputation or mixed-effects models for repeated mea-
surements (MMRM) have become more of a standard. While the
latter methods seem somewhat better than LOCF (Leon 2006),
we feel that the high percentage of participants leaving the studies
early and differences in the reasons for leaving the studies early be-
tween groups is often the core problem in randomised schizophre-
nia trials. We will therefore not exclude studies based on the sta-
tistical approach used. However, we will preferably use the more
sophisticated approaches (e.g. MMRM or multiple-imputation
rather than LOCF) and we will only present completer analyses if
some kind of ITT data are not available at all. Moreover, we will
address this issue in the item “incomplete outcome data” of the
’Risk of bias’ tool.
Assessment of heterogeneity
1. Clinical heterogeneity
Wewill consider all included studies initially, without seeing com-
parison data, to judge clinical heterogeneity. We will simply in-
spect all studies for clearly outlying people or situations which we
had not predicted would arise and discuss.
2. Methodological heterogeneity
Wewill consider all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity.We will sim-
ply inspect all studies for clearly outlying methods which we had
not predicted would arise and discuss.
3. Statistical heterogeneity
3.1 Visual inspection
We will visually inspect graphs to investigate the possibility of
statistical heterogeneity.
3.2 Employing the I² statistic
We will investigate heterogeneity between studies by considering
the I² method alongside the Chi² P value. The I² provides an es-
timate of the percentage of inconsistency thought to be due to
chance (Higgins 2003). The importance of the observed value of
I² depends on i. magnitude and direction of effects and ii. strength
of evidence for heterogeneity (e.g. P value from Chi² test, or a
confidence interval for I²). We will interpret an I² estimate greater
than or equal to around 50% accompanied by a statistically sig-
nificant Chi² statistic as evidence of substantial levels of hetero-
geneity (see section 9.5.2 of Cochrane Handbook for Systematic Re-
views of Interventions - Higgins 2011). When substantial levels of
heterogeneity are found in the primary outcome, we will explore
reasons for heterogeneity (Subgroup analysis and investigation of
heterogeneity).
Assessment of reporting biases
1. Protocol versus full study
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results. These are de-
scribed in section 10.1 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We will try to locate pro-
tocols of included randomised trials. If the protocol is available,
we will compare outcomes in the protocol and in the published
report. If the protocol is not available, we will compare outcomes
listed in the Methods section of the trial report with actually re-
ported results.
2. Funnel plot
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results (Egger 1997).
These are again described in Section 10 of theCochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).We are aware
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that funnel plots may be useful in investigating reporting biases
but are of limited power to detect small-study effects. We will
not use funnel plots for outcomes where there are 10 or fewer
studies, or where all studies are of similar size. In other cases, where
funnel plots are possible, we will seek statistical advice in their
interpretation.
Data synthesis
We understand that there is no closed argument for preference for
use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating different, yet related, intervention effects. This often
seems to be true to us and the random-effects model takes into
account differences between studies even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model: it puts added weight onto small studies
which often are the most biased ones. Depending on the direction
of effect these studies can either inflate or deflate the effect size.
We choose the random-effects model for all analyses.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
1.1 Primary outcomes
No subgroup analysis is planned.
1.2 Clinical state, stage or problem
We propose to undertake this review and provide an overview of
the effects of pharmacological augmentation of clozapine for peo-
ple with schizoaffective disorder in general. In addition, however,
we will try to report data on subgroups of people in the same clin-
ical state, stage and with similar problems.
2. Investigation of heterogeneity
Wewill report high inconsistency. First we will investigate whether
data have been entered correctly. Second, if data are correct, wewill
visually inspect the graph and successively remove studies outside
of the company of the rest to see if homogeneity is restored. For
this review we have decided that should this occur with data con-
tributing to the summary finding of no more than around 10%
of the total weighting, we will present these data. If not, we will
not pool data and will discuss issues. We know of no supporting
research for this 10% cut-off but are investigating use of predic-
tion intervals as an alternative to this unsatisfactory state.
When unanticipated clinical or methodological heterogeneity are
obvious we will simply state hypotheses regarding these for future
reviews or versions of this review.Wedonot anticipate undertaking
analyses relating to these.
Sensitivity analysis
1. Implication of randomisation
We aim to include trials in a sensitivity analysis if they are described
in some way as to imply randomisation. For the primary outcomes
wewill include these studies and if there is no substantive difference
when the implied randomised studies are added to those with
better description of randomisation, then we will use all relevant
data from these studies.
2. Assumptions for lost binary data
Where assumptions have to be made regarding people lost to fol-
low-up (see Dealing with missing data) we will compare the find-
ings of the primary outcomes when we use our assumption/s and
when we use data only from people who complete the study to
that point. If there is a substantial difference, we will report results
and discuss them but will continue to employ our assumption.
Where assumptions have to be made regarding missing SDs data
(see Dealing with missing data), we will compare the findings of
the primary outcomeswhenwe use our assumption/s andwhenwe
use data only from people who complete the study to that point.
A sensitivity analysis will be undertaken testing how prone results
are to change when completer-only data only are compared to the
imputed data using the above assumption. If there is a substantial
difference, wewill report results anddiscuss thembutwill continue
to employ our assumption.
3. Risk of bias
We will analyse the effects of excluding trials that are judged to be
at high risk of bias across one or more of the domains of randomi-
sation (implied as randomised with no further details available,
allocation concealment, blinding and outcome reporting) for the
meta-analysis of the primary outcome. If the exclusion of trials at
high risk of bias does not substantially alter the direction of effect
or the precision of the effect estimates, then we will include data
from these trials in the analysis.
4. Imputed values
We will also undertake a sensitivity analysis to assess the effects of
including data from trials where we use imputed values for ICC
in calculating the design effect in cluster randomised trials.
If substantial differences are noted in the direction or precision of
effect estimates in any of the sensitivity analyses listed above, we
will not pool data from the excluded trials with the other trials
contributing to the outcome, but will present them separately.
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5. Fixed and random effects
Wewill synthesise all data using a random-effects model; however,
we will also synthesise data for the primary outcome using a fixed-
effect model to evaluate whether this alters the significance of the
results
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